Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Table 1 Baseline characteristics of patients in COMPACT long-term, open-label study (HRQoL population)

	C1-INH(SC) 40 IU/kg N = 63	C1-INH(SC) 60 IU/kg N = 63	All C1-INH(SC) N = 126
Age, years, mean (SD)^a	40.8 (14.96)	40.3 (16.26)	40.5 (15.56)
Range	8–67	10–72	8–72
Female, n (%)	40 (63.5)	36 (57.1)	76 (60.3)
Mean body weight, kg (SD)	86.1 (23.27)	84.26 (24.24)	85.2 (23.68)
Mean BMI, kg/m² (SD)	29.6 (6.92)	28.8 (7.56)	29.2 (7.23)
Race, n (%)
White	60 (95.2)	61 (96.8)	121 (96.0)
Black or African American	1 (1.6)	1 (1.6)	2 (1.6)
Asian	0	1 (1.6)	1 (0.8)
Other	2 (3.2)	0	2 (1.6)
HAE history, n (%)
C1-INH(SC)-HAE type I	55 (87.3)	58 (92.1)	113 (89.7)
C1-INH(SC)-HAE type II	8 (12.7)	5 (7.9)	13 (10.3)
Mean (SD) number HAE attacks in 3 months before screening^b	12.8 (8.42)	12.7 (10.23)	12.8 (9.33)
Prior use of prophylaxis (preceding 3 months), n (%)	39 (61.9)	40 (63.5)	79 (62.7)
Prior prophylaxis medication
C1-INH(SC) (COMPACT study)	32 (50.8)	32 (50.8)	64 (50.8)
C1-INH(IV)	6 (9.5)	5 (7.9)	11 (8.7)
Oral prophylaxis (danazol)	1 (1.6)	3 (4.8)	4 (3.2)

BMI body mass index, HAE hereditary angioedema, SD standard deviation, C1-INH(SC) subcutaneous C1-inhibitor, HRQoL health-related quality of life, C1-INH(IV) intravenous C1-inhibitor
^aTen patients were < 18 years old (range: 8–16 years, with three patients < 12 years old) and 10 patients were ≥ 65 years old (range: 65–72 years)
^bFor C1-INH(SC)-naïve subjects and C1-INH(SC)-interrupted subjects, “screening” was the first visit of the open-label study; for C1-INH(SC)-continuation subjects, the screening visit was prior to entry into the double-blind COMPACT study

ISSN: 1750-1172